Carfilzomib, lenalidomide, dexamethasone ( KRD ) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19617 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Federica Cavallo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology U, University Hospital AOU Città della Salute e della Scienza, Turin, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Lenalidomide, Lymphoma, Mantle-Cell. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Mantle cell lymphoma (MCL) is a rare lymphoproliferative neoplasm considered incurable, with a median survival of 3–5 years. In recent years, Bruton's tyrosine kinase inhibitors (BTKi) have been introduced, demonstrating high therapeutic activity. However, the prognosis for MCL patients failing ibrutinib therapy is particularly poor, with a survival expectation of a few months. In this phase II trial, we assessed the efficacy and safety of the carfilzomib‐lenalidomide‐dexamethasone (KRD) combination in MCL patients who were relapsed/refractory (R/R) or intolerant to BTKi and in need of treatment. The primary objective of the study was to evaluate the antitumor efficacy of the KRD combination in terms of 12‐month overall survival (12‐month OS). From September 2019 to December 2020, 16 patients were enrolled from 11 Italian centers. After a median follow‐up of 2.37 months (95% CI 0.92–6.47), the 12‐month OS was 13%. The rate of grade 3–4 adverse events (AEs) was 35%, and the overall response rate (ORR) was 19%. These results led to the premature termination of enrollment, as defined in the protocol stopping rules. The efficacy of the KRD combination in advanced‐stage MCL patients who are R/R to BTKi is unsatisfactory and too toxic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology U, University Hospital AOU Città della Salute e della Scienza, Turin, Italy.
- Division of Hematology U, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy.
- UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Ospedale Maggiore, Trieste, Italy.
- Unit of Cancer Epidemiology (CPO Piemonte) and University of Turin, Turin, Italy.
- Division of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
- Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
ORCID-Profile: Federica Cavallo, Elisa Lucchini, Luca Arcaini
Zitieren
APA
Cavallo, F., Clerico, M., Lucchini, E., Castiglione, A., Re, A., Zilioli, V. R., Visco, C., Tani, M., Olivieri, J., Arcaini, L., Fabbri, A., Gaidano, G., Dodero, A., & Zaja, F. (2024). Carfilzomib, lenalidomide, dexamethasone ( KRD ) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi. British Journal of Haematology. https://doi.org/10.1111/bjh.19617
Vancouver
Cavallo F, Clerico M, Lucchini E, Castiglione A, Re A, Zilioli VR, et al. Carfilzomib, lenalidomide, dexamethasone ( KRD ) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi. British Journal of Haematology. 2024. doi:10.1111/bjh.19617
BibTeX
@article{Cavallo2024,
author = {Cavallo, Federica and Clerico, Michele and Lucchini, Elisa and Castiglione, Anna and Re, Alessandro and Zilioli, Vittorio Ruggiero and Visco, Carlo and Tani, Monica and Olivieri, Jacopo and Arcaini, Luca and Fabbri, Alberto and Gaidano, Gianluca and Dodero, Anna and Zaja, Francesco},
title = {Carfilzomib, lenalidomide, dexamethasone ( KRD ) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19617}
}
EUVIMED